Diabetes

Research Highlights Benefits of Aspirin, Monoclonal Antibody Use in Patients With Diabetes, COVID-19

September 10th 2021, 7:00pm

Article

New research presented at the 5th Heart in Diabetes Conference highlights potential therapeutic options for patients with COVID-19 and diabetes.

FDA Grants Empagliflozin Breakthrough Therapy Designation in HFpEF

September 9th 2021, 3:00pm

Article

The sodium glucose co-transporter 2 (SGLT2) inhibitor reduced cardiovascular death and hospitalization for heart failure by 21% in results presented August 27 during the recent European Society of Cardiology Congress.

Dr David McIntyre on Care Takeaways From COVID-19 for Pregnant Patients With Diabetes

September 7th 2021, 8:00pm

Video

David McIntyre, MD, FRACP, describes lessons learned from the pandemic for ensuring appropriate continuation of care for pregnant patients with diabetes.

Increase in Both Type 1 and Type 2 Diabetes Seen Among US Youth Over 16-Year Period

September 2nd 2021, 9:03pm

Article

Native American and Black youth aged 10 to 19 years had the highest incidence of type 2 diabetes overall.

Dr Deepak L. Bhatt Discusses SGLT Inhibitors’ Impact on Glycemic Control

August 30th 2021, 3:45pm

Video

Deepak L. Bhatt, MD, MPH, executive director of interventional cardiovascular programs at Brigham and Women’s Hospital Heart & Vascular Center and professor of medicine at Harvard Medical School, outlines the role that sodium glucose co-transporter (SGLT) inhibitors play in patients with diabetes and diminished glomerular filtration rates.

USPSTF Lowers Recommended T2D, Prediabetes Screening Age to 35 Years

August 26th 2021, 4:00pm

Article

The United States Preventive Services Task Force (USPSTF) lowered its recommended screening age for type 2 diabetes and prediabetes from 40 to 35 years among overweight and obese individuals.

Cost-effectiveness of Intensification With SGLT2 Inhibitors for Type 2 Diabetes

August 25th 2021, 4:00pm

Article

Adding a sodium-glucose co-transporter 2 (SGLT2) inhibitor dominated switching to a glucagon-like peptide 1 receptor agonist over the lifetimes of patients with type 2 diabetes not at glycated hemoglobin A1c target after treatment with metformin plus a dipeptidyl peptidase-4 inhibitor.

FDA Approves Empagliflozin to Treat HFrEF Regardless of T2D Status

August 19th 2021, 5:15pm

Article

The FDA has approved empagliflozin (Jardiance) for adults with heart failure with reduced ejection fraction, regardless of type 2 diabetes status.

Jump in US Gestational Diabetes Rates Seen Across All Racial, Age Groups

August 17th 2021, 3:30pm

Article

An analysis of gestational diabetes trends in the United States revealed increases across all age and racial subgroups over the past decade.

Catlin Dennis Outlines Lessons Learned From COVID-19 for Vulnerable Youth With Diabetes

August 16th 2021, 3:26pm

Video

Catlin Dennis, MPH, explains the importance of securing internet and technology access among vulnerable youth with diabetes.